One-two particle punch poses greater risk for astronauts

August 24, 2006

UPTON, NY - It doesn't just matter how much radiation an astronaut is exposed to, time and the order in which charged particles strike human cells are important factors as well. That's the main finding of a study simulating radiation exposure conducted at the U.S. Department of Energy's Brookhaven National Laboratory and published in the September 2006 edition of Radiation Research. In the study, human cells were three times more likely to develop properties similar to those in the initial stages of cancer when they were exposed to two types of high-energy particles in a short period of time.

The radiation field in space contains high levels of high-energy protons and much lower levels of high atomic number, high-energy (HZE) particles such as iron and titanium.

"Most people studying the effects of space radiation have looked at the effects of just one type of particle, either the protons or the HZE particles," said Brookhaven biologist Betsy Sutherland, the paper's lead author. "This is one of the first studies to try to imitate real space radiation conditions closely, where, on average, a cell will be hit by a proton first and then by an HZE particle. We decided to examine what this does to human cells."

To test the effect of dual-particle irradiation, Sutherland's team at the NASA Space Radiation Laboratory, a facility built at Brookhaven Lab specifically for space radiation studies, first exposed normal human cells to a beam of protons. Then, anywhere from 2.5 minutes to 48 hours later, they exposed the cells to iron or titanium particles. After

allowing the cells to grow, the researchers counted the number of cells that survived to form colonies and those that acquired the ability to grow without being affixed to a solid surface. This characteristic, known as anchorage-independent growth, is an early indicator that these cells might be on the pathway to cancer.

"There are a lot of animal-based systems for measuring the induction of cancer, but you can't just take human cells and treat them with radiation or chemicals and immediately get cancer cells," Sutherland said. "You have to do several treatments in order to get a real cancer cell. Some people study the end stages of this process, but we look at the very first step."

The research team found that the probability that cells undergo this initial transformation depends on the time interval between the cell's exposure to protons and HZE particles. When the cells received both irradiations within 2.5 minutes to one hour, they produced about three times more anchorage-independent colonies per survivor than expected from the sum of the effects of the two radiation exposures.

"If you hit cells in less than an hour with a little tickle of protons and, on average, one iron ion per cell, that's when you get the big increase in transformation," Sutherland said. "If this were to happen in space, a certain fraction of the astronaut's cells would have a higher risk of going along this initial path to cancer development."

The good news, Sutherland said, is that in real space, most of the charged particle hits do not occur that close together in time. Therefore, only a small part of the astronaut's cells would have an increased risk of becoming cancerous.

The reason for the observed increase in anchorage independence in response to the one-two particle punch is not yet clear. The obvious effects - those related to survival or the cell cycle - tuned out not to be the cause of increased transformation, Sutherland said. The team observed a further complication when the order of particle exposure was reversed; there was no increase in anchorage independence when the cells were hit with either an iron or titanium particle first, followed by protons.

"Now our challenge is to figure out exactly what is happening," Sutherland said, adding that the results of this study and projects like it help NASA assess the hazards of space travel. "If we're going to send people into space, it's our responsibility to tell them what their risks are and investigate ways to mitigate the danger."
This research was funded by the NASA Biomedical Research & Countermeasures Program, the National Space Biomedical Research Institute, the National Institutes of Health, and by the Office of Biological and Environmental Research of the U.S. Department of Energy's Office of Science.

One of ten national laboratories overseen and primarily funded by the Office of Science of the U.S. Department of Energy (DOE), Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. Brookhaven Lab also builds and operates major scientific facilities available to university, industry and government researchers. Brookhaven is operated and managed for DOE's Office of Science by Brookhaven Science Associates, a limited-liability company founded by the Research Foundation of State University of New York on behalf of Stony Brook University, the largest academic user of Laboratory facilities, and Battelle, a nonprofit, applied science and technology organization. Visit Brookhaven Lab's electronic newsroom for links, news archives, graphics, and more:

DOE/Brookhaven National Laboratory

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to